Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Notes Tables

Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]

	September 30,		December 31,
	2023		2022
Cash and cash equivalents	$	3,472	$	5,362
Restricted cash included in other assets		476		484
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows	$	3,948	$	5,846

Schedules of Concentration of Risk, by Product [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Avenova Spray	$	2,064	$	1,939	$	5,759	$	5,778
DERMAdoctor		784		1,319		2,645		3,115
NeutroPhase		—		—		1,043		657
Other products		407		558		1,524		1,193
Total product revenue, net		3,255		3,816		10,971		10,743
Other revenue, net		10		10		28		18
Total sales, net	$	3,265	$	3,826	$	10,999	$	10,761

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	September 30,			December 31,
Major distribution partner	2023			2022
Major U.S. Retailer A		26	%		*	%
Avenova Spray Pharmacy Distributor A		20	%		11	%
Major International Retailer A		10	%		*	%
Avenova Spray Pharmacy Distributor B		*	%		30	%
Major U.S. Retailer B		*	%		15	%

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
Numerator	2023			2022*			2023			2022*
Net loss	$	(1,757	)	$	(136	)	$	(5,532	)	$	(2,402	)
Less: Increase in accumulated deficit due to Series B Preferred Stock conversion price		—			(5,657	)		(1,802	)		(5,657	)
Less: Increase in accumulated deficit due to Series C Preferred Stock conversion price		—			—			(194	)		—
Net loss attributable to common stockholders (basic and diluted)	$	(1,757	)	$	(5,793	)	$	(7,528	)	$	(8,059	)
Denominator
Weighted average shares of common stock outstanding (basic and diluted)		4,692			1,604			3,311			1,514
Net loss per share (basic and diluted)	$	(0.37	)	$	(3.61	)	$	(2.27	)	$	(5.32	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	As of September 30,
	2023		2022
Series B Preferred Stock		4,736		1,845
Series C Preferred Stock		845		—
Stock options		148		136
Stock warrants		7,382		65
		13,111		2,046